Health Care • Biotechnology: Pharmaceutical Preparations
$13.81 ▲ +0.03
(+0.22%)
MKT CAP: $3.63B • VOL: 2.51M
52W L $6 52W H $14
ROARABLE / RQD
C- • 61/100
PIOTROSKI
6 / 9
OGN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.22B | $6.40B | $6.26B |
| YoY Revenue Growth % | -2.9% | +2.2% | — |
| Gross Profit | $3.31B | $3.71B | — |
| Gross Margin % | 53.3% | 58.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $187.0M | $864.0M | $1.02B |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $700.0M | $939.0M | $799.0M |
| Capital Expenditures (CapEx) | $162.0M | $175.0M | — |
| Free Cash Flow (FCF) | $538.0M | $764.0M | $799.0M |
| FCF Margin % | 8.7% | 11.9% | 12.8% |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $574.0M | $675.0M | — |
| Total Debt (Short + Long Term) | $8.63B | $8.86B | — |
| Total Stockholders' Equity | $752.0M | $472.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR OGN.